Yang et al. have suggested that in breast tumors, TAMs are responsible for chemotherapy drug resistance via the interleukin 10 (IL-10)/signal transducer and activator of transcription 3 (STAT3)/B-cell lymphoma 2 (Bcl-2) signaling pathway [122]. The gene discussed is IL10; the disease is breast neoplasm.